Annual report
4005.TEDINET S100VXZW
Period2024-04-01 → 2025-03-31
Filed2025-06-20
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 152
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.61T | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥2.45T | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥2.90T | 2022-04-01 → 2023-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥2.77T | 2021-04-01 → 2022-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥2.29T | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥193.0bn | 2024-04-01 → 2025-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | −¥488.8bn | 2023-04-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥58.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | −¥462.8bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥231m | 2022-04-01 → 2023-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥251.1bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥137.8bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥38.6bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥311.8bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥7.0bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥162.1bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥46.0bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥42.7bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss IFRS |
| Net income | −¥465.4bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Net income | −¥46.9bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥186.4bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥68.1bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss IFRS (5-year summary) |
| Total assets | ¥3.44T | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥3.93T | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥4.17T | at 2023-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥4.31T | at 2022-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥3.99T | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥2.37T | at 2025-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥2.77T | at 2024-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.07T | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.16T | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.49T | at 2023-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥900.8bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥965.8bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.17T | at 2023-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥1.22T | at 2022-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥1.02T | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥209.8bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥217.4bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥305.8bn | at 2023-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥365.4bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥360.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥233.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | −¥51.3bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥111.6bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥171.7bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥374.5bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | ¥85.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥112.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥19.4bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥115.4bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥177.4bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥300.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥49.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥178.5bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥81.4bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥40.0bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥23.59 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-190.69 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥4.27 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥99.16 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥28.16 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥23.58 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥4.27 | 2022-04-01 → 2023-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥550.37 | at 2025-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥590.44 | at 2024-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥716.26 | at 2023-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥745.03 | at 2022-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥623.39 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 26.2% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 24.5% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 28.1% | at 2023-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 28.3% | at 2022-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 25.5% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 4.1% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | -29.2% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 0.6% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 14.5% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 4.7% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 29,279 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 32,161 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 33,572 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 34,703 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 34,743 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥856.6bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥809.6bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥894.4bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥797.4bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥646.0bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥59.7bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥2.4bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥84.9bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥53.4bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥69.5bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥68.5bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥38.1bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥42.9bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥10.2bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥24.2bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥8.7bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥50.4bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥61.7bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥41.7bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.82T | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥1.90T | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥1.77T | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.74T | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.73T | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.42T | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥1.53T | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥393.9bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥370.4bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥378.0bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥368.8bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥346.2bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥85.7bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥69.0bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥14.77 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥5.32 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥30.85 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥37.76 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥25.52 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥9 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥9 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥18 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥24 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥240.68 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥226.42 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥231.14 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥225.56 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥211.77 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 21.7% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 19.5% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 21.3% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 21.2% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.0% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 6.3% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.3% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 13.5% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 17.3% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.6% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 1,657,217,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,656,449,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,655,860,000 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,655,446,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,655,446,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 6,669 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 6,706 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 6,637 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 6,488 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 6,277 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 104
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2024-04-01 → 2025-03-31 | ¥4.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-03-31 | 1344 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2025-03-31 | ¥165.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥99.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥65.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2025-03-31 | ¥284.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥66.9bn |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥7.2bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥85.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥85.4bn |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥102.2bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥32.7bn |
| Advanced Medical Solutionsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥13.0bn |
| Advanced Medical Solutionsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥72.5bn |
| Advanced Medical Solutionsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥62.1bn |
| Advanced Medical Solutionsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥10.4bn |
| Advanced Medical Solutionsreportable segment | segment assets | at 2025-03-31 | ¥125.3bn |
| Advanced Medical Solutionsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥4.0bn |
| Agro And Life Solutionsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥20.1bn |
| Agro And Life Solutionsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥541.3bn |
| Agro And Life Solutionsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥540.2bn |
| Agro And Life Solutionsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥1.1bn |
| Agro And Life Solutionsreportable segment | segment assets | at 2025-03-31 | ¥771.3bn |
| Agro And Life Solutionsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥55.0bn |
| Energy And Functional Materialsreportable segment | employees | at 2025-03-31 | 9620 pure |
| Essential And Green Materialsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥26.3bn |
| Essential And Green Materialsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥903.9bn |
| Essential And Green Materialsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥899.0bn |
| Essential And Green Materialsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥4.9bn |
| Essential And Green Materialsreportable segment | segment assets | at 2025-03-31 | ¥791.9bn |
| Essential And Green Materialsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥58.5bn |
| Essential Chemicals And Plasticsreportable segment | employees | at 2025-03-31 | 7366 pure |
| Health And Agriculture Relatedreportable segment | employees | at 2025-03-31 | 3609 pure |
| ICT And Mobility Solutionsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥49.2bn |
| ICT And Mobility Solutionsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥610.3bn |
| ICT And Mobility Solutionsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥607.0bn |
| ICT And Mobility Solutionsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥3.3bn |
| ICT And Mobility Solutionsreportable segment | segment assets | at 2025-03-31 | ¥635.7bn |
| ICT And Mobility Solutionsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥70.6bn |
| Information Electronic Chemistryreportable segment | employees | at 2025-03-31 | 2115 pure |
| Medical Productsreportable segment | employees | at 2025-03-31 | 3828 pure |
| Sumitomo Pharmareportable segment | capex | 2024-04-01 → 2025-03-31 | ¥11.5bn |
| Sumitomo Pharmareportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥398.5bn |
| Sumitomo Pharmareportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥398.0bn |
| Sumitomo Pharmareportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥529m |
| Sumitomo Pharmareportable segment | segment assets | at 2025-03-31 | ¥728.7bn |
| Sumitomo Pharmareportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥35.3bn |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥120.1bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥2.53T |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥2.51T |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥20.2bn |
| —segment total | segment assets | at 2025-03-31 | ¥3.05T |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥106.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2023-04-01 → 2024-03-31 | ¥5.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2024-03-31 | ¥162.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥85.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥76.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-03-31 | ¥426.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | ¥11.6bn |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥9.4bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥102.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥102.7bn |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥45.1bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥27.6bn |
| Advanced Medical Solutionsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥7.9bn |
| Advanced Medical Solutionsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥73.4bn |
| Advanced Medical Solutionsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥58.5bn |
| Advanced Medical Solutionsreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥14.9bn |
| Advanced Medical Solutionsreportable segment | segment assets | at 2024-03-31 | ¥118.4bn |
| Advanced Medical Solutionsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥6.1bn |
| Agro And Life Solutionsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥27.8bn |
| Agro And Life Solutionsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥517.6bn |
| Agro And Life Solutionsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥515.6bn |
| Agro And Life Solutionsreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥2.0bn |
| Agro And Life Solutionsreportable segment | segment assets | at 2024-03-31 | ¥842.8bn |
| Agro And Life Solutionsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥26.4bn |
| Essential And Green Materialsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥29.2bn |
| Essential And Green Materialsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥891.0bn |
| Essential And Green Materialsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥885.9bn |
| Essential And Green Materialsreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥5.1bn |
| Essential And Green Materialsreportable segment | segment assets | at 2024-03-31 | ¥953.4bn |
| Essential And Green Materialsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥89.1bn |
| ICT And Mobility Solutionsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥61.9bn |
| ICT And Mobility Solutionsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥591.1bn |
| ICT And Mobility Solutionsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥587.4bn |
| ICT And Mobility Solutionsreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥3.7bn |
| ICT And Mobility Solutionsreportable segment | segment assets | at 2024-03-31 | ¥649.6bn |
| ICT And Mobility Solutionsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥50.0bn |
| Sumitomo Pharmareportable segment | capex | 2023-04-01 → 2024-03-31 | ¥16.3bn |
| Sumitomo Pharmareportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥313.9bn |
| Sumitomo Pharmareportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥313.8bn |
| Sumitomo Pharmareportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥95m |
| Sumitomo Pharmareportable segment | segment assets | at 2024-03-31 | ¥899.6bn |
| Sumitomo Pharmareportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥126.4bn |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥143.1bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥2.39T |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥2.36T |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥25.8bn |
| —segment total | segment assets | at 2024-03-31 | ¥3.46T |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | −¥133.1bn |
| Energy And Functional Materialsreportable segment | employees | at 2025-03-31 | 1847 pure |
| Essential Chemicals And Plasticsreportable segment | employees | at 2025-03-31 | 1470 pure |
| Health And Agriculture Relatedreportable segment | employees | at 2025-03-31 | 1513 pure |
| Information Electronic Chemistryreportable segment | employees | at 2025-03-31 | 600 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,606
| Item | Context | Value | Unit |
|---|---|---|---|
| Metrics description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | Original text (Japanese)管理社員登用者における女性比率 | |
| Target period description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | Original text (Japanese)2023～2027年度 | |
| Metrics unit description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | ％ | |
| Metrics description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | Original text (Japanese)子が出生した男性社員の、育児休業もしくは育児関連諸休暇の当年度中取得率 | |
| Metrics unit description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | ％ | |
| Metrics description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | Original text (Japanese)自己応募型研修プログラムの受講率 | |
| Target period description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | Original text (Japanese)2024年度 | |
| Metrics unit description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | ％ | |
| Metrics description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row4Member | Original text (Japanese)「健康経営優良法人（ホワイト500）」の継続認定 | |
| Reference to other information description of metrics related to policy on human resource development and improvement of internal environment and targets and results using such metrics | FilingDateInstant | Original text (Japanese)サステナビリティレポート2024（P.147～164）及びサステナビリティレポート2025（2025年８月末発行予定） | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts (text) | FilingDateInstant | Text · Plus | |
| Research and development activities (text) | FilingDateInstant | Text · Plus | |
| Overview of capital expenditures etc (text) | FilingDateInstant | Text · Plus | |
| Major facilities (text) | FilingDateInstant | Text · Plus | |
| Planned additions retirements etc of facilities (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所プライム市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数は100株であります。 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Description of rights plan (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Shareholding by shareholder category (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | CurrentYearInstant_No1MajorShareholdersMember | Original text (Japanese)日本マスタートラスト信託銀行株式会社（信託口） | |
| Address major shareholders | CurrentYearInstant_No1MajorShareholdersMember | Original text (Japanese)東京都港区赤坂一丁目８番１号 | |
| Name major shareholders | CurrentYearInstant_No2MajorShareholdersMember | Original text (Japanese)株式会社日本カストディ銀行（信託口） | |
| Address major shareholders | CurrentYearInstant_No2MajorShareholdersMember | Original text (Japanese)東京都中央区晴海一丁目８番12号 | |
| Name major shareholders | CurrentYearInstant_No3MajorShareholdersMember | Original text (Japanese)住友生命保険相互会社 | |
| Address major shareholders | CurrentYearInstant_No3MajorShareholdersMember | Original text (Japanese)東京都中央区八重洲二丁目２番１号 | |
| Name major shareholders | CurrentYearInstant_No4MajorShareholdersMember | Original text (Japanese)日本生命保険相互会社 | |
| Address major shareholders | CurrentYearInstant_No4MajorShareholdersMember | Original text (Japanese)東京都千代田区丸の内一丁目６番６号 | |
| Name major shareholders | CurrentYearInstant_No5MajorShareholdersMember | Original text (Japanese)住友化学社員持株会 | |
| Address major shareholders | CurrentYearInstant_No5MajorShareholdersMember | Original text (Japanese)東京都中央区日本橋二丁目７番１号 | |
| Name major shareholders | CurrentYearInstant_No6MajorShareholdersMember | Text · Plus | |
| Address major shareholders | CurrentYearInstant_No6MajorShareholdersMember | Text · Plus | |
| Name major shareholders | CurrentYearInstant_No7MajorShareholdersMember | Original text (Japanese)ＪＰモルガン証券株式会社 | |
| Address major shareholders | CurrentYearInstant_No7MajorShareholdersMember | Original text (Japanese)東京都千代田区丸の内二丁目７番３号 | |
| Name major shareholders | CurrentYearInstant_No8MajorShareholdersMember | Original text (Japanese)株式会社日本カストディ銀行（三井住友信託銀行再信託分・住友生命保険相互会社退職給付信託口） | |
| Address major shareholders | CurrentYearInstant_No8MajorShareholdersMember | Original text (Japanese)東京都中央区晴海一丁目８番12号 | |
| Name major shareholders | CurrentYearInstant_No9MajorShareholdersMember | Text · Plus | |
| Address major shareholders | CurrentYearInstant_No9MajorShareholdersMember | Text · Plus | |
| Name major shareholders | CurrentYearInstant_No10MajorShareholdersMember | Original text (Japanese)農林中央金庫 | |
| Address major shareholders | CurrentYearInstant_No10MajorShareholdersMember | Original text (Japanese)東京都千代田区大手町一丁目２番１号 | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |